Publications Archive - Page 2 of 5 - KalVista Pharmaceuticals

Showing 11-20 out of 43

Phase 3 KONFIDENT Trial of Oral Sebetralstat for Treatment of Hereditary Angioedema Attacks: Analysis of the European and US Patient Subgroups

Zanichelli A, Aygören-Pürsün E, Bernstein JA, Farkas H, Lumry WR, Maurer M, Riedl MA, Hao J, Smith MD, Audhya PK, Yea C, Cohn DM

Impact of Oral Sebetralstat on Anxiety Associated with Hereditary Angioedema Attacks in the Phase 3 KONFIDENT Trial

Maurer M, Cohn DM, Bernstein JA, Farkas H, Lumry WR, Riedl MA, Zanichelli A, Hao J, Smith MD, PK Audhya, Yea CM, Aygören-Pürsün E

Patient-Reported Benefits of Early On-demand Treatment of HAE Attacks

Guilarte M, Longhurst H, van Kooten S, Malloy N, Heckmann M, Busse P

Delayed On-demand Treatment of Hereditary Angioedema Attacks and Associated Barriers Reported by Italian Patients

Cancian M

A Specific, Sensitivity Assay Measuring Patient Sample Plasma Kallikrein Activity

Lee D

Pooled Sebetralstat Placebo-controlled Safety for On-demand Treatment of Hereditary Angioedema (Oral Presentation)

Aygören-Pürsün E

Pooled Sebetralstat Placebo-controlled Efficacy for On-demand Treatment of Hereditary Angioedema (Poster Presentation)

Aygören-Pürsün E

Closing Gaps in Hereditary Angioedema Management: Addressing Delays in On-Demand Treatment

Jones D, Buttgereit T, Carne E, Cohn D

Hereditary Angioedema (HAE) Patients Answer: Why Do Attacks Go Untreated?

Radojicic C, Busse P, O’Connor M, Danese S, Ulloa J, Desai V, Andriotti T, Audhya PK, Christiansen S
EAACI 2024

Attack Characteristics in Patients with Hereditary Angioedema Receiving Non-Androgen Long-term Prophylaxis

Lumry W, Baptist A, Soteres D, Manning M, Earl L, Connolly H, Audhya PK, Wang A, Andriotti T, Desai V
EAACI 2024

About